Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease

Bioengineered particles expand myelin-specific regulatory T cells and reverse autoreactivity in a mouse model of multiple sclerosis

(2023) Kelly R. Rhodes et al.   Science Advances

Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia

(2022) Earl Sands et al.   Nature Communications

Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein

(2022) Seymour de Picciotto et al.   Nature Communications

Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation

(2022) Yusuke Meguri et al.   Frontiers in Immunology

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection

(2022) Derek VanDyke et al.   Cell Reports

Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles

(2021) Petr O. Ilyinskii et al.   Science Advances

TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study

(2021) Ciarán P. Kelly et al.   GASTROENTEROLOGY

Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation

(2021) Claudia Selck et al.   Frontiers in Immunology

Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles

(2021) Petr O. Ilyinskii et al.   Frontiers in Immunology

Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies

(2020) Takashi Kei Kishimoto   Frontiers in Immunology

Defining the Threshold IL-2 Signal Required for Induction of Selective Treg Cell Responses Using Engineered IL-2 Muteins

(2020) Aazam Ghelani et al.   Frontiers in Immunology

The Surprising Story of IL-2

(2020) Abul K. Abbas   AMERICAN JOURNAL OF PATHOLOGY

Regulatory T cells: Master thieves of the immune system

(2020) Billur Akkaya et al.   CELLULAR IMMUNOLOGY

Persistent IL-2 Receptor Signaling by IL-2/CD25 Fusion Protein Controls Diabetes in NOD Mice by Multiple Mechanisms

(2020) Natasha C. Ward et al.   DIABETES

An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice

(2020) Liliane Khoryati et al.   Science Immunology

Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?

(2020) Ibo Janssens et al.   CELLULAR IMMUNOLOGY

Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species

(2020) Ufuk Karakus et al.   Science Translational Medicine

Engineering IL-2 to Give New Life to T Cell Immunotherapy

(2020) Willem W. Overwijk et al.   Annual Review of Medicine

Regulatory T cells mediate specific suppression by depleting peptide–MHC class II from dendritic cells

(2019) Billur Akkaya et al.   NATURE IMMUNOLOGY

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

(2019) Kevan C. Herold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial

(2019) Jing He et al.   ANNALS OF THE RHEUMATIC DISEASES

Hybrid insulin peptides are neo-epitopes for CD4 T cells in autoimmune diabetes

(2019) Rocky L. Baker et al.   Current Opinion in Endocrinology Diabetes and Obesity

A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism

(2018) Eleonora Trotta et al.   NATURE MEDICINE

Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis

(2018) Jeremy Chataway et al.   NEUROLOGY

Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity

(2018) Ronit Mazor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis

(2018) Robert A. LaMothe et al.   Frontiers in Immunology

Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy

(2018) Jamie B. Spangler et al.   JOURNAL OF IMMUNOLOGY

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

(2018) Michelle Rosenzwajg et al.   ANNALS OF THE RHEUMATIC DISEASES

Treg cells—the next frontier of cell therapy

(2018) Jeffrey A. Bluestone et al.   SCIENCE

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

(2018) Amine Meliani et al.   Nature Communications

Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells

(2017) Joshua D. Ooi et al.   NATURE

Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans

(2016) Petra Bacher et al.   CELL

A roadmap of the generation of neoantigens as targets of the immune system in type 1 diabetes

(2016) Bart O Roep et al.   CURRENT OPINION IN IMMUNOLOGY

Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles

(2016) Takashi K. Kishimoto et al.   Nature Nanotechnology

Antigen exposure shapes the ratio between antigen-specific Tregs and conventional T cells in human peripheral blood

(2016) Laura F. Su et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

(2015) Caroline von Spee-Mayer et al.   ANNALS OF THE RHEUMATIC DISEASES

Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells

(2015) Charles J.M. Bell et al.   JOURNAL OF AUTOIMMUNITY

CD4+CD25+ Foxp3+ Regulatory T Cells Protect against T Cell-Mediated Fulminant Hepatitis in a TGF- -Dependent Manner in Mice

(2014) H.-X. Wei et al.   JOURNAL OF IMMUNOLOGY

Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance

(2014) Roberto A. Maldonado et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout

(2014) Peter E Lipsky et al.   ARTHRITIS RESEARCH & THERAPY

Immune responses to AAV vectors: overcoming barriers to successful gene therapy

(2013) F. Mingozzi et al.   BLOOD

Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

(2013) Wei Liao et al.   IMMUNITY

Do MHCII-Presented Neoantigens Drive Type 1 Diabetes and Other Autoimmune Diseases?

(2013) P. Marrack et al.   Cold Spring Harbor Perspectives in Medicine

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs  -Cell Function

(2012) S. A. Long et al.   DIABETES

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhancement of antigen-specific Treg vaccination in vivo

(2010) C. Daniel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Autoantigens in systemic autoimmunity: critical partner in pathogenesis

(2009) A. Rosen et al.   JOURNAL OF INTERNAL MEDICINE

Immunity to Citrullinated Proteins in Rheumatoid Arthritis

(2008) Lars Klareskog et al.   Annual Review of Immunology

Combination of rapamycin and IL-2 increases de novo induction of human CD4+CD25+FOXP3+ T cells

(2008) S. Alice Long et al.   JOURNAL OF AUTOIMMUNITY

The Biology of Interleukin-2

(2007) Thomas R. Malek   Annual Review of Immunology